VEC Share Price

Open 112.60 Change Price %
High 112.60 1 Day -2.70 -2.39
Low 110.20 1 Week -0.90 -0.81
Close 110.20 1 Month -2.80 -2.48
Volume 2134813 1 Year -33.80 -23.47
52 Week High 166.97
52 Week Low 109.50
VEC Important Levels
Resistance 2 112.42
Resistance 1 111.51
Pivot 111.00
Support 1 108.89
Support 2 107.98
LON UK Most Active Stocks
CWC 74.60 0.27%
CWC 74.60 0.27%
CWC 74.60 0.27%
INC 0.04 -20.00%
LLOY 63.91 -0.76%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
IRG 0.40 0.00%
LON UK Top Gainers Stocks
AKT 28.50 5177.78%
HHR 58.00 900.00%
MLD 10.00 700.00%
MES 0.28 75.00%
MES 0.28 75.00%
MES 0.28 75.00%
PFLM 5.75 64.29%
BAC 22.54 61.00%
BAC 22.54 61.00%
BAC 22.54 61.00%
LON UK Top Losers Stocks
ENDV 0.02 -99.85%
KEA 0.10 -91.30%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
ACU 0.05 -87.50%
DCP 0.50 -75.61%
PCI 3.50 -53.27%
PCI 3.50 -53.27%
BHR 0.02 -33.33%
NBR 0.25 -24.24%

Vectura Group PLC (LON: VEC)

VEC Technical Analysis 5
As on 18th Aug 2017 VEC Share Price closed @ 110.20 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 134.10 & Strong Sell for SHORT-TERM with Stoploss of 113.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
VEC Target for August
1st Target up-side 118.41
2nd Target up-side 121.42
3rd Target up-side 124.44
1st Target down-side 109.79
2nd Target down-side 106.78
3rd Target down-side 103.76
VEC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
VEC Address
One Prospect West
Chippenham, SN14 6FH
United Kingdom
Phone: 44 1249 667700
Fax: 44 1249 667701
VEC Latest News
Needle Action Activity Spotted in Vectura Group PLC (VEC.L)   Morgan Research   - 18th Aug 17
Vectura Group to hook up with Dynavax to develop cancer treatment   Proactive Investors UK   - 16th Aug 17
Vectura reports wider loss but revenue jumps after Skyepharma merger   Proactive Investors UK   - 21st Mar 17
Calculating the intrinsic value of Vectura Group plc (LSE:VEC)   Simply Wall St   - 21st Mar 17
Will Vectura Group plc outperform AstraZeneca plc after today's results gain a ...   Motley Fool UK   - 11th Jan 17
Vectura Group plc: Pre-close update   GlobeNewswire (press release)   - 11th Jan 17
Vectura Group plc: Licensing agreement signed for the launch of Utibron/Seebri ...   GlobeNewswire (press release)   - 21st Dec 16
Could Vectura Group plc grow to be a FTSE 100 company within 10 years?   Motley Fool UK   - 23rd Nov 16
This unfancied drug stock has the potential to soar   Proactive Investors UK   - 07th Sep 16
Vectura Group PLC and Hikma shares given FDA boost   Proactive Investors UK   - 08th Apr 16
Interactive Technical Analysis Chart Vectura Group PLC ( VEC LON UK )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Vectura Group PLC
VEC Business Profile
Vectura Group plc develops pharmaceutical therapies for the treatment of bronchopulmonary diseases. Its products target various diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company offers ADVATE, a serum-free recombinant factor VIII for haemophilia A; Adept, a 4% icodextrin solution used during surgery to reduce post-surgical adhesions; Extraneal, a solution containing icodextrin for peritoneal dialysis; and Seebri Breezhaler, a long-acting muscarinic antagonist for the treatment of COPD, as well as Asmasal Clickhaler, Asmabec Clickhaler, and Meptin for the treatment of asthma. Its product pipeline comprises QVA149, a fixed-dose combination of indacaterol maleate and glycopyrronium bromide for the treatment of adult patients with COPD; VR315 and VR632 that are inhaled combination therapies for asthma and COPD; VR506, an inhaled corticosteriod for the treatment of asthma; VR496, an inhaled, locally acting treatment for symptoms of inflammatory respiratory disease; and VR040, an inhaled, systemically acting form of apomorphine hydrochloride for treating off episodes associated with advanced Parkinson's disease. The company also provides various drug delivery technology platforms, such as PowderHale, a dry powder inhalation (DPI) formulation technology that is designed to allow aerosolized drug particles to achieve high lung deposition with low-dose variability; GyroHaler and OmniHaler, which are multi-unit dose DPI devices designed to deliver locally acting drugs to the lungs; Clickhaler, a single-dose inhaler; and Duohaler, a dry powder inhaler. It has development collaborations and license agreements with Novartis AG, Sandoz, Baxter International Inc, GlaxoSmithKline, and Tianjin KingYork Group Company Limited. The company was founded in 1997 and is headquartered in Chippenham, the United Kingdom.